Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar
Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar patents invalidated.
Lunar, of Madison, WI, fired the opening salvo last month whenit filed a federal lawsuit in U.S. District Court for the EasternDistrict of Wisconsin (SCAN 9/14/94). Lunar said that Hologic'smorphometry process is covered by three Lunar patents and askedthe court to overturn several Hologic patents.
Hologic's countersuit, filed in U.S. District Court for theDistrict of Massachusetts, charges that Lunar is infringing ontwo of Hologic's patents and asks for injunctive relief and damages.The complaint also seeks a declaration that Hologic does not infringeon three Lunar patents, which should be invalidated, accordingto the company. Finally, Hologic is asking for injunctive reliefand damages in connection with what the company said was "Lunar'sdissemination of false and misleading information which misrepresentsand disparages the quality of Hologic's bone densitometry products."
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.